I note that Dew has not yet been kind enough to accept my invitation to handicap the probabilities of success for us. The same invitation goes to all who come to share their worries, like Rockrat. Some concerns might even be valid, up to a point. It sure doesn't hurt to rehearse possible glitches in case there really is a showstopper.
The "beef" is probability of success. Unless that probability is very low, RPRX is a screaming buy. And unless worries are couched in these risk-return terms, the commentator is either insincere or financially innumerate. So c'mon guys, with your little niggles about 85% powered and two times this, bring it down to brass tacks. Are you saying there's a 90% chance the PIIIs will fail? 80%? 70%? Or 5%? Because we are being paid to accept less than certainty of success, to put it mildly!
BTW, re angst about the ex-US trial: I don't know that anyone has pointed out that the ex-US market for Proellex is huge. At Repros's modest Proellex price assumption and consequent favorable cost-effectiveness ratio, Europe will be a very accessible market. If an overseas trial expedites access to Europe, the value of RPRX is that much higher.
Market Data 
Markets 
